Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Financing Cash Flow history
Currency unavailable · from the cash flow
No Financing Cash Flow data reported for this period type.
Financing Cash Flow vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $830.71M USD | +390.1% | — | — |
| LTM Sep 2026 | $759.69M USD | +242.5% | +93.5% | 839.5% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M USD | +53.0% | -72.7% | 4878.8% |
| LTM Mar 2026 | $254.22M USD | +330054.5% | -11.9% | — | |
| LTM Mar 2026 | $102.81M USD | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $52.19M USD | -29.8% | — | 623.8% | |
| LTM Jun 2026 | $41.61M USD | +36.7% | +6.7% | 14.8% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +53.0% | -2.6% | 623.8% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.